Related references
Note: Only part of the references are listed.Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week
Dirk Schuermann et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2022)
A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951-2021)
Guangdi Li et al.
MEDICINAL RESEARCH REVIEWS (2022)
Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK-8507, an Investigational, Oral, Once-Weekly Nonnucleoside Reverse Transcriptase Inhibitor
Gillian Gillespie et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus
Paul E. Sax et al.
CLINICAL INFECTIOUS DISEASES (2021)
Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study
Guangdi Li et al.
AGING-US (2021)
Examining the Safety, Pharmacokinetics, and Pharmacodynamics of a Rectally Administered IQP-0528 Gel for HIV Pre-Exposure Prophylaxis: A First-In-Human Study
Amer Al-Khouja et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2021)
Druggability modification strategies of the diarylpyrimidine-type non-nucleoside reverse transcriptase inhibitors
Li Ding et al.
MEDICINAL RESEARCH REVIEWS (2021)
Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq
Guangdi Li et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Avoiding Drug Resistance in HIV Reverse Transcriptase
Maria E. Cilento et al.
CHEMICAL REVIEWS (2021)
Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday
Guangdi Li et al.
MOLECULES (2021)
Cytoplasmic synthesis of endogenous Alu complementary DNA via reverse transcription and implications in age-related macular degeneration
Shinichi Fukuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study
Annalene Nel et al.
Lancet HIV (2021)
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
Jared M Baeten et al.
Lancet HIV (2021)
An overview of ProTide technology and its implications to drug discovery
Michaela Serpi et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants
Rima K. Acosta et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs
Betty Ha et al.
NATURE COMMUNICATIONS (2021)
Where are we with drug treatments for covid-19?
Chris Baraniuk
BMJ-BRITISH MEDICAL JOURNAL (2021)
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Chloe Orkin et al.
Lancet HIV (2021)
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial
Jean-Michel Molina et al.
LANCET HIV (2021)
SARS-CoV-2 cell entry and targeted antiviral development
Zinuo Chen et al.
ACTA PHARMACEUTICA SINICA B (2021)
Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective
Miao Miao et al.
BIOMEDICINES (2021)
Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
Wendy Ankrom et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel
Xin Jin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs
Li Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors
Tessa Senneker et al.
CURRENT OPINION IN HIV AND AIDS (2021)
Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients
Jose J. Garcia-Trejo et al.
FRONTIERS IN ONCOLOGY (2021)
Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses
Yue Ma et al.
CHEMICAL SOCIETY REVIEWS (2021)
An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status
Young Hyun Shin et al.
INFECTION AND CHEMOTHERAPY (2021)
Biocatalytic routes to anti-viral agents and their synthetic intermediates
Sjoerd Slagman et al.
CHEMICAL SOCIETY REVIEWS (2021)
Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3
Martin Markowitz et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs
Dongwei Kang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities
Krishnaveni Reddy et al.
AIDS (2020)
Topical Microbicides in HIV Prevention: State of the Promise
Jared M. Baeten et al.
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
Kaijun Jin et al.
ACTA PHARMACEUTICA SINICA B (2020)
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
Chunlin Zhuang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H
Lei Wang et al.
ACCOUNTS OF CHEMICAL RESEARCH (2020)
Clinical significance of chemokine receptor antagonists
Miao Miao et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2020)
Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study
Min Zhang et al.
HEPATOLOGY INTERNATIONAL (2020)
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
Scott L. Letendre et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses
Na Xu et al.
JOURNAL OF VIROLOGY (2020)
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Guangdi Li et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Chloe O. C. Orkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Susan Swindells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prodrugs of γ-Alkyl-Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase
Chenglong Zhao et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons
Courtney V. Fletcher et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
Dirk Schuermann et al.
LANCET HIV (2020)
Clinical characteristics of older and younger patients infected with SARS-CoV-2
Zhiguo Zhou et al.
AGING-US (2020)
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy A Cohort Study
Julia del Amo et al.
ANNALS OF INTERNAL MEDICINE (2020)
A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study
Zhigang Ren et al.
ADVANCED SCIENCE (2020)
Mechanistic Insight into Antiretroviral Potency of 2′-Deoxy-2′-β-fluoro-4′-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention
Li Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Kenneth H Mayer et al.
LANCET (2020)
Clinical targeting of HIV capsid protein with a long-acting small molecule
John O. Link et al.
NATURE (2020)
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0
L. Ryom et al.
HIV MEDICINE (2020)
Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy
Miao Miao et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development
Jayakrishna Ambati et al.
NATURE COMMUNICATIONS (2020)
HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates
Soo-Yon Rhee et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2020)
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Edgar T. Overton et al.
LANCET (2020)
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
Mark J. Siedner et al.
NATURE COMMUNICATIONS (2020)
Recent discoveries in HIV-1 reverse transcriptase inhibitors
Shuang-Xi Gu et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Design strategies for long-acting anti-HIV pharmaceuticals
Yali Sang et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens
Murugesan Vanangamudi et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Chuanhao Jiang et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
Chloe Orkin et al.
CLINICAL INFECTIOUS DISEASES (2019)
Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans
Rosa I. Sanchez et al.
XENOBIOTICA (2019)
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir
Wendy Ankrom et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions
Sauzanne G. Khalilieh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1
Ka Lai Yee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vitro Evaluation of the Drug Interaction Potential of Doravirine
Kelly Bleasby et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors
Gaetana Sterrantino et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
Margaret Johnson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Fifty Years in Search of Selective Antiviral Drugs
Erik De Clercq
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 non-nucleoside reverse transcriptase inhibitor binding pocket
Shuang-Xi Gu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
Willem D. F. Venter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment
Yali Wang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
Alexander Wong et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
Cissy Kityo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Epistasis and entrenchment of drug resistance in HIV-1 subtype B
Avik Biswas et al.
ELIFE (2019)
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
Franco Maggiolo et al.
LANCET HIV (2019)
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients
Cathia Soulie et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Design of an invitro biocatalytic cascade for the manufacture of islatravir
Mark A. Huffman et al.
SCIENCE (2019)
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial
Joseph J. Eron et al.
LANCET HIV (2019)
No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration
Matt S. Anderson et al.
ANTIVIRAL THERAPY (2019)
The ProTide Prodrug Technology: From the Concept to the Clinic
Youcef Mehellou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Joseph J. Eron et al.
AIDS (2018)
Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention
Stephanie E. Barrett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics
Wendy Ankrom et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections
Erik De Clercq
BIOCHEMICAL PHARMACOLOGY (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women Text
Sally Hodder et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)
Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals
Rebecca Begley et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)
Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes
Duncan T. Njenda et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Rare emergence of drug resistance in HIV-1 treatment-naive patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks
Nicolas Margot et al.
JOURNAL OF CLINICAL VIROLOGY (2018)
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
Josep M. Llibre et al.
LANCET (2018)
Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs
Dhwanil A. Dalwadi et al.
PHARMACOLOGICAL REVIEWS (2018)
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Chloe Orkin et al.
LANCET HIV (2018)
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
Jean-Michel Molina et al.
LANCET HIV (2018)
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Jean-Michel Molina et al.
LANCET HIV (2018)
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Eric S. Daar et al.
LANCET HIV (2018)
HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise
Craig W. Hendrix
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells
Lin Song et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa
Kerri J. Penrose et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics
Sauzanne Khalilieh et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Intestinal absorption mechanisms of 2′-deoxy-2′-β-fluoro-4′-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein
Yixian Liu et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide
Nicolas A. Margot et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Paul E. Sax et al.
LANCET (2017)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel Gallant et al.
LANCET (2017)
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
Paul E. Sax et al.
LANCET HIV (2017)
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Edwin DeJesus et al.
LANCET HIV (2017)
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Chloe Orkin et al.
LANCET HIV (2017)
In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection
Nicholas S. Giacobbi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
MK-8591 (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture
Vincent H. Wu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Current therapy for chronic hepatitis C: The role of direct-acting antivirals
Guangdi Li et al.
ANTIVIRAL RESEARCH (2017)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
S. K. Sarin et al.
HEPATOLOGY INTERNATIONAL (2016)
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
Joseph M. Custodio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations
Meizhen Feng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
Erik De Clercq
BIOCHEMICAL PHARMACOLOGY (2016)
Approved Antiviral Drugs over the Past 50 Years
Erik De Clercq et al.
CLINICAL MICROBIOLOGY REVIEWS (2016)
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals
Julia L. Marcus et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants
Steven J. Smith et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Anton Pozniak et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics
Barbara A. Friedland et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Anthony Mills et al.
LANCET INFECTIOUS DISEASES (2016)
The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
Huilian Wang et al.
MEDICINE (2016)
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women
A. Nel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Novel antiretroviral agents and universal access to HIV care
Mark A. Boyd et al.
LANCET HIV (2016)
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
Nicholas T. Funderburg et al.
EBIOMEDICINE (2016)
In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate
Christian Callebaut et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Oral Administration of the Nucleoside EFdA (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque
Cheryl A. Stoddart et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention
Anthony S. Ham et al.
ANTIVIRAL RESEARCH (2015)
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
Anthony Mills et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy
Shweta R. Ugaonkar et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Paul E. Sax et al.
LANCET (2015)
An integrated map of HIV genome-wide variation from a population perspective
Guangdi Li et al.
RETROVIROLOGY (2015)
An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014 - Erik De Clercq
Erik De Clercq
ACTA PHARMACEUTICA SINICA B (2015)
In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways
Meizhen Feng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects
Matt S. Anderson et al.
ANTIVIRAL THERAPY (2015)
A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women
Annalene Nel et al.
AIDS (2014)
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
Calvin Cohen et al.
AIDS (2014)
In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor
Ming-Tain Lai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses
Bernard Cote et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy
Paul E. Sax et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms
Eleftherios Michailidis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Quantification of 2′-deoxy-2′-β-fluoro-4′-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies
Youmei Peng et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)
Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro
Rui-Rui Wang et al.
PLOS ONE (2014)
Development of dapivirine vaginal ring for HIV prevention
Brid Devlin et al.
ANTIVIRAL RESEARCH (2013)
Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults
Peter J. Ruane et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340
Darius Babusis et al.
MOLECULAR PHARMACEUTICS (2013)
In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine
Susan M. Schader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine In Vitro and In Vivo
Michael Murphey-Corb et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro
Eve-Irene Lepist et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates
Yubing Zhou et al.
ANTIVIRAL THERAPY (2012)
Vaginal Microbicide Gel for Delivery of IQP-0528, a Pyrimidinedione Analog with a Dual Mechanism of Action against HIV-1
Alamelu Mahalingam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase
Robert Gomez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
The Nonnucleoside Reverse Transcriptase Inhibitor MIV-150 in Carrageenan Gel Prevents Rectal Transmission of Simian/Human Immunodeficiency Virus Infection in Macaques
R. Singer et al.
JOURNAL OF VIROLOGY (2011)
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
Jean-Michel Molina et al.
LANCET (2011)
TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
Hilde Azijn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation
Gerben Van 't Klooster et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.
Robert M. Grant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safety and Availability of Dapivirine (TMC120) Delivered from an Intravaginal Ring
J. Romano et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2009)
Safety and Pharmacokinetics of Dapivirine Delivery From Matrix and Reservoir Intravaginal Rings to HIV-Negative Women
Annalene Nel et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
The Design, Synthesis, and Antiviral Activity of Monofluoro and Difluoro Analogues of 4′-Azidocytidine against Hepatitis C Virus Replication: The Discovery of 4′-Azido-2′-deoxy-2′-fluorocytidine and 4′-Azido-2′-dideoxy-2′,2′-difluorocytidine
David B. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations
Thomas J. Tucker et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
2 '-deoxy-4 '-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants
Atsushi Kawamoto et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Discovery of 3-{5-[(6-Amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A Potent, Orally Bioavailable HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor with Improved Potency against Key Mutant Viruses
Thomas J. Tucker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
2′-deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-α-hydroxyl groups
Klaus Klumpp et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2
Robert W. Buckheit et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA Polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosine
Hirotorao Nakata et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication:: The discovery of R1479
David B. Smith et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains
Celine Mordant et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2007)
Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond
Tomas Cihlar
CURRENT OPINION IN HIV AND AIDS (2006)
Short-term antiviral activity of TMC278 -: a novel NNRTI -: in treatment-naive HIV-1-infected subjects
Frank Goebel et al.
AIDS (2006)
Tetrazole thioacetanilides: Potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant
E Muraglia et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings
RK Malcolm et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue
WA Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1
J Guillemont et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
In search of a novel anti-HIV drug:: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6dimethylphenyl] amino]-2-pyrimidinyl]amino]-benzonitrile (R278474, rilpivirine)
PAJ Janssen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1
K Andries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides
Y Van Herrewege et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides
Y Van Herrewege et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Evolution of anti-HIV drug candidates.: Part 1:: From α-anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU)
DW Ludovici et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Evolution of anti-HIV drug candidates part 2:: Diaryltriazine (DATA) analogues
DW Ludovici et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Evolution of anti-HIV drug candidates.: Part 3:: Diarylpyrimidine (DAPY) analogues
DW Ludovici et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340
H Chapman et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2001)
Purification of PMPA amidate prodrugs by SMB chromatography and X-ray crystallography of the diastereomerically pure GS-7340
H Chapman et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2001)
Share Paper
